Undertreatment of hypercholesterolemia

Area of Science:

• Cardiology
• Public Health
• Pharmacology

Background:

• Current guidelines advocate stringent low-density lipoprotein cholesterol (LDL-C) targets (1.8-2.6 mmol/L; 70-100 mg/dL) for cardiovascular risk reduction.
• Despite recommendations, a significant number of patients, particularly those in primary and secondary prevention, remain suboptimally controlled.
• This suboptimal control is attributed to both under-prescription of lipid-lowering therapies and poor patient adherence to prescribed regimens.

Discussion:

• Two recent studies highlight the under-treatment of hypercholesterolemia across European nations.
• These studies identify specific patient and physician characteristics associated with inadequate LDL-C control.
• The findings underscore a gap between evidence-based guidelines and clinical practice in managing hypercholesterolemia.

Key Insights:

• Under-prescription of lipid-lowering medications is a significant barrier to achieving target LDL-C levels.
• Patient adherence to prescribed lipid-lowering therapy is crucial for effective hypercholesterolemia management.
• Variations in patient and physician factors contribute to the observed disparities in LDL-C control.

Outlook:

• There is a substantial need for improved strategies to enhance the prescription and adherence of lipid-lowering medications.
• Further research should focus on identifying and addressing the root causes of under-treatment in diverse patient populations.
• Continued efforts are required to bridge the gap between guideline recommendations and real-world clinical practice for optimal cardiovascular disease prevention.